<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        166-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOVIRAX 250MG IV INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ACYCLOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        140.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zovirax I.V. (called &lsquo;Zovirax&rsquo; in this leaflet) contains a medicine called aciclovir. This belongs to a group of medicines called antivirals. It works by killing or stopping the growth of viruses.</p><p>Zovirax can be used to:</p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;treat chickenpox</p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;treat severe cases of genital herpes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; treat and stop cold sores and genital herpes in people whose immune systems work less well, which means their bodies are less able to fight infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; treat serious virus infections in children up to 3 months of age. This can rarely be caused by the virus responsible for cold sore infection and genital herpes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; treat inflammation of the brain. This can rarely be caused by the virus responsible for cold sore infection and genital herpes</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not have Zovirax:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; if you are allergic to aciclovir or valaciclovir or any of the other ingredients of this medicine (listed in Section 6).</p><p>Do not take Zovirax if the above applies to you. If you are not sure, talk to your doctor or pharmacist before having Zovirax.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your<strong> </strong>doctor or pharmacist before having Zovirax if:</p><p>&middot;&nbsp;&nbsp;&nbsp; you have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp; you are over 65 years of age.</p><p>If you are not sure if the above apply to you, talk to your doctor or pharmacist before taking Zovirax.</p><p>It is important that you drink plenty of water while taking Zovirax</p><p><strong>Other medicines and Zovirax</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp; probenecid, used to treat gout</p><p>&middot;&nbsp;&nbsp;&nbsp; cimetidine, used to treat stomach ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp; tacrolimus, ciclosporin or mycophenolate mofetil, used to stop your body rejecting transplanted organs</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Zovirax contains sodium</strong></p><p>Zovirax contains 26 mg sodium per dose. To be taken&nbsp;into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How your medicine is given</strong></p><p>You will never be expected to give yourself this medicine. It will always be given to you by a person who is trained to do so.</p><p>Before the medicine is given to you it will be diluted.</p><p>Zovirax will be given to you as a continuous infusion into your vein. This is where the drug is slowly given to you over a period of time.</p><p>The dose you will be given, the frequency and the duration of the dose will depend on:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the type of infection you have</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; your weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; your age</p><p><strong>&nbsp;</strong></p><p><strong>Your doctor may adjust the dose of Zovirax if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems. If you have kidney problems, it is important you receive plenty of fluids while you are being treated with Zovirax.</p><p>Talk to your doctor before having Zovirax if any of the above apply.</p><p><strong>&nbsp;</strong></p><p><strong>If you are given too much Zovirax </strong></p><p>If you think you have been given too much Zovirax, talk to your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you have been given too much Zovirax you may:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feel confused or agitated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have hallucinations (seeing or hearing things that aren&rsquo;t there)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have fits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; become unconscious (coma)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Allergic reactions </strong>(may affect up to 1 in 10,000 people)</p><p>If you have an allergic reaction, <strong>stop taking Zovirax and see a doctor straight away</strong>. The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itching or hives on your skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, lips, tongue or other parts of your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, wheezing or trouble breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained fever (high temperature) and feeling faint, especially when standing up.</p><p>&nbsp;</p><p>Other side effects include:</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or being sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy, hive-like rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reaction after exposure to light (photosensitivity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, redness and tenderness at the site of injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of white blood cells (leukopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of blood platelets (cells that help the blood to clot) (thrombocytopenia)</p><p><strong>&nbsp;</strong></p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache or feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea or stomach pains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on some blood urine tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated or confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shaking or tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations (seeing or hearing things that aren&rsquo;t there)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unusually sleepy or drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unsteadiness when walking and lack of coordination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty speaking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to think or judge clearly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unconsciousness (coma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paralysis of part or all of your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbances of behaviour, speech and eye movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiff neck and sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of your skin and whites of your eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems where you pass little or no urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your lower back, the kidney area of your back or just above your hip (renal pain)</p><p>&nbsp;</p><p><strong>If you get side effects</strong></p><p>&egrave;&nbsp; <strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep this medicine out of the sight and reach of children.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the carton after &lsquo;EXP&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 25&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor told you to stop taking this medicine return any unused Zovirax to your pharmacist to be destroyed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Zovirax I.V. contains<br />&bull; The active substance is aciclovir.<br />&bull; The other ingredient is sodium hydroxide.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zovirax I.V. is supplied in glass vials, containing an off-white powder. The 250 mg strength is available in 17 ml vials, in a box containing 5 vials.

ZOVIRAX IV is a trademark owned by or licensed to GSK group of companies
© 2023 GSK group of companies


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer </strong></p><p>GlaxoSmithKline Manufacturing S.p.A.*, Parma, Italy</p><p><strong>Marketing Authorisation Holder</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>*member of the GlaxoSmithKline group of companies</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: &nbsp;npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: &nbsp;https://ade.sfda.gov.sa</p><p><strong>&nbsp;-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: &nbsp;saudi.safety@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: &nbsp;https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>THIS IS A MEDICAMENT</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicine out of reach of children.</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: UK issue 10 draft 1
Date of issue: 05 August 2021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زوفيراكس الوريدي (المسمى &quot;زوفيراكس&quot; في هذه النشرة) على دواء اسمه أسيكلوفير. وهو ينتمي إلى فئة من الأدوية تسمى مضادات الفيروسات. ويظهر تأثيره العلاجي بالقضاء على نمو الفيروسات أو إيقافه.</p><p dir="RTL">يمكن استخدام زوفيراكس للأغراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;علاج الحماق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;علاج الحالات الحادة لهربس الأعضاء التناسلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; علاج قرحات الزكام وهربس الأعضاء التناسلية وإيقافها لدى الأشخاص الذين يعانون من ضعف الجهاز المناعي، مما يعني أن أجسامهم أقل قدرةً على مكافحة العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; علاج العدوى الفيروسية الخطيرة في الأطفال حتى 3 أشهر من العمر. نادرًا ما قد يحدث هذا بفعل الفيروس المسؤول عن عدوى قرحات الزكام وهربس الأعضاء التناسلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; علاج التهاب الدماغ. نادرًا ما قد يحدث هذا بفعل الفيروس المسؤول عن عدوى قرحات الزكام وهربس الأعضاء التناسلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تجنّب استخدام زوفيراكس:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود حساسية لمادة الأسيكلوفير أو الفالسيكلوفير أو لأيّ مكوّن من المكوّنات الأخرى الخاصة بهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">لا تستخدم زوفيراكس إذا كانت أي من الحالات السابقة تنطبق عليك. وفي حالة عدم التأكد من ذلك، ينبغي استشارة الطبيب أو الصيدلي قبل استخدام زوفيراكس.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل استخدام زوفيراكس في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وجود مشكلات في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد عن 65 عامًا.</p><p dir="RTL">في حالة عدم التأكد مما إذا كان ما ذُكر أعلاه ينطبق عليك، ينبغي استشارة الطبيب أو الصيدلي قبل تناول زوفيراكس.</p><p dir="RTL">من المهم أن تشرب قدرًا وفيرًا من الماء أثناء تناول زوفيراكس</p><p dir="RTL"><strong>الأدوية الأخرى وزوفيراكس</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخرًا أو قد تتناول أدوية أخرى. ويشمل ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية، بما في ذلك الأدوية العشبية.</p><p dir="RTL">بصفة خاصة، ينبغي عليك إخبار الطبيب أو الصيدلي إذا كنت تتناول أي دواء من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بروبينسيد، المستخدم لعلاج النقرس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; السيميتيدين&rlm;‫، المستخدم لعلاج قرح المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التاكروليموس أو سيكلوسبورين أو ميكوفينولات موفيتيل، المستخدم لمنع رفض جسمك للأعضاء المزروعة</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">في حالة الحمل أو الرضاعة الطبيعية أو إذا كنتِ تظنين أنكِ حامل أو تخططين للحمل، فيجب استشارة الطبيب أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زوفيراكس يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي زوفيراكس على 26 ملجم من الصوديوم لكل جرعة. ينبغي على المرضى، الذين يتبعون نظامًا غذائيًا للتحكم في مستوى الصوديوم، أخذ هذا الأمر بعين الاعتبار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفية إعطاء الدواء الخاص بك</strong></p><p dir="RTL">ليس من المتوقع أبدًا أن تعطي لنفسك هذا الدواء. ينبغي دائمًا أن يكون من يعطيك هذا الدواء شخصًا متدربًا على القيام بهذا.</p><p dir="RTL">قبل إعطاء الدواء لك سيتم تخفيفه.</p><p dir="RTL">سيتم إعطاء زوفيراكس لك كتسريب مستمر في وريدك. هذا هو المكان الذي يتم إعطاء الدواء لك فيه ببطء خلال فترة زمنية.</p><p dir="RTL">ستتوقف الجرعة التي سيتم إعطاؤها لك ومعدل تكرارها ومدتها على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نوع العدوى التي تعاني منها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وزنك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عمرك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد يقوم الطبيب بتعديل جرعة زوفيراكس في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود مشكلات في الكلى. إذا كنت تعاني من مشكلات بالكلى، فإنه من المهم أن تحصل على قدر وفير من السوائل أثناء علاجك بدواء زوفيراكس.</p><p dir="RTL">ينبغي استشارة الطبيب قبل تناول زوفيراكس أو في حالة وجود أيّ مما سبق.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا أُعطيت جرعة زائدة من زوفيراكس </strong></p><p dir="RTL">إذا كنت تعتقد أنه قد تم إعطاؤك جرعة زائدة من زوفيراكس، ينبغي استشارة الطبيب أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُعطيت جرعة زائدة من زوفيراكس فقد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشعر بالارتباك أو الاضطراب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من الهلاوس (رؤية أو سماع أشياء غير موجودة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفقد الوعي (الغيبوبة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث أعراض جانبية، لكن ليس بالضرورة أن يُصاب بها جميع الأشخاص. قد تحدث الآثار الجانبية التالية عند تناول هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong> (قد تؤثر على نسبة تصل إلى شخص واحد من كل 10,000 شخص)</p><p dir="RTL">في حالة الإصابة بتفاعل الحساسية، <strong>ينبغي التوقف عن تناول زوفيراكس واستشارة طبيب على الفور</strong>. قد تشمل العلامات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح أو الحكة أو الشرى على جلدك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم وجهك أو شفتيك أو لسانك أو أجزاء أخرى من جسمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس أو أزيز في الصدر أو صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى مجهولة السبب (ارتفاع درجة الحرارة) والشعور بالإغماء، ولا سيما عند الوقوف</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الأخرى:</p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على نسبة تصل إلى شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك أو الإعياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة، طفح يشبه الانتبار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل البشرة بعد التعرض للضوء (الحساسية للضوء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم، والاحمرار، والألم في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أنزيمات الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تؤثر على نسبة تصل إلى شخص واحد من كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (قلة الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية (خلايا تساعد الدم في التجلط) (نقص الصفائح الدموية)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار النادرة جدًا</strong> (قد تؤثر على نسبة تصل إلى شخص واحد من كل 10,000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع أو الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو آلام المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإجهاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثيرات على بعض اختبارات الدم والبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالاضطراب أو الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف أو الرعاش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهلاوس (رؤية أو سماع أشياء غير موجودة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالخمول أو النعاس غير المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الثبات أثناء المشي وفقد الاتزان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الكلام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز عن التفكير أو الحكم بوضوح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي (الغيبوبة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شلل جزء من الجسم أو الجسم كله</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات السلوك والكلام وحركات العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس الرقبة والحساسية للضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (الوبائي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو بياض العينين (اليرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلى حيث تُخرج قليلاً من البول أو لا تُخرجه على الإطلاق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أسفل الظهر، منطقة الكلى في الظهر أو أعلى الورك مباشرةً (ألم كلوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإصابة بالآثار الجانبية</strong></p><p dir="RTL">&ccedil;&nbsp;&nbsp; <strong>أبلغ الطبيب أو الصيدلي</strong> في حالة <strong>تفاقم</strong> أي من الأعراض الجانبية الموضحة هنا أو <strong>إذا أصبحت مزعجة</strong>، أو إذا لاحظت أي أعراض جانبية غير مبيَّنة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يجب حفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تخزين الدواء في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بالتوقف عن تناول هذا الدواء، فيجب عليك إعادة أي كمية غير مستخدمة من زوفيراكس إلى الصيدلي ليتم إعدامها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية برميها في مياه الصرف أو ضمن المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها.<br />من شأن هذه الإجراءات أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتوى زوفيراكس الوريدي<br />&bull; المادة الفعَّالة هي أسيكلوفير.<br />&bull; المكوّن الآخر هو هيدروكسيد الصوديوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل زوفيراكس ومحتويات العبوة</strong></p><p dir="RTL">&rlm;‫يتم توفير زوفيراكس الوريدي في قنينات زجاجية ويحتوي على مسحوق أبيض. ويتوفر تركيز 250 ملجم في قنينات مقاس 17 مل، في عبوة تحتوي على<br />5 قنينات..&nbsp;</p><p dir="RTL"><strong>زوﭬـيراكس</strong> علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2023 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">جلاكسو سميث كلاين إس.بي.أيه.*، بارما، إيطايا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صاحبة رخصة التسويق</strong></p><p dir="RTL">.Glaxo Saudi Arabia Ltd* ﺟﺪة، اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ</p><p dir="RTL">اﻟﻌﻨﻮان: ص. ب. 22617 ﺟﺪة 21416 &ndash; اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ.</p><p dir="RTL">إحدى شركات GlaxoSmithKline.</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL"><strong>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 966126536666+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: 966569049882+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : gcc.medinfo@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع إلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية.</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية </strong><strong>(</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666 (12) 966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال : 9882-904-56 &nbsp;966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد اللكتروني : saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p><p dir="RTL"><!--[if gte vml 1]><v:roundrect
 id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_5" o:spid="_x0000_s1027"
 style='position:absolute;left:0;text-align:left;margin-left:430.7pt;
 margin-top:296.2pt;width:481.9pt;height:215.4pt;z-index:251662336;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:right;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="2.5pt">
 <v:shadow color="#868686"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL><b><span lang=AR-SA style='mso-bidi-font-size:
    14.0pt;font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>إن
    هذا دواء<o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>-
    الدواء مستحضر يؤثر على صحتك، وإستهلاكه خلافا للتعليمات يعرضك للخطر.<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>-
    اتبع بدقة وصفة الطبيب، وطريقة الإستعمال المنصوص عليها، وتعليمات الصيدلاني
    الذي صرفها لك.<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>-
    فالطبيب و الصيدلاني هما الخبيران بالدواء، وبنفعه و ضرره.<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>-
    لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>-
    لا تكرر صرف الدواء بدون إستشارة الطبيب.<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'>-
    احتفظ بجميع الأدوية بعيداً عن متناول الأطفال.<span
    style='mso-spacerun:yes'>    </span><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'><span
    style='mso-tab-count:8'>                                                                                  </span>مجلس
    وزراء الصحة العرب <o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=AR-SA style='mso-bidi-font-size:14.0pt;
    font-family:"Traditional Arabic",serif;mso-fareast-font-family:Calibri'><span
    style='mso-tab-count:8'>                                                                                  </span><span
    style='mso-spacerun:yes'>   </span>اتحاد الصيادلة العرب<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span lang=EN-GB dir=LTR style='mso-bidi-font-family:
    Arial'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><v:roundrect id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_6"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:162.1pt;margin-top:18.15pt;width:481.9pt;height:250.5pt;z-index:251665408;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="2.5pt">
 <v:shadow color="#868686"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL><b><span lang=AR-SA style='font-size:16.0pt;
    font-family:"Traditional Arabic",serif'>للإبلاغ عن أية آثار جانبية:</span></b><b><span
    lang=EN-GB dir=LTR style='font-size:16.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL><b><i><span lang=AR-SA style='font-size:16.0pt;
    font-family:"Traditional Arabic",serif'>المملكة العربية السعودية</span></i></b><b><i><span
    lang=EN-GB dir=LTR style='font-size:16.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></i></b></p>
    <p class=MsoNormal dir=RTL><span dir=RTL></span><b><span lang=AR-SA
    style='mso-bidi-font-size:14.0pt;font-family:"Traditional Arabic",serif'><span
    dir=RTL></span>- المركز الوطني للتيقظ والسلامة الدوائية </span></b><b><span
    lang=AR-SA style='mso-bidi-font-size:14.0pt;font-family:"Calibri",sans-serif;
    mso-fareast-language:EN-GB'>(</span></b><b><span dir=LTR style='mso-bidi-font-size:
    14.0pt;font-family:"Traditional Arabic",serif;mso-ansi-language:EN-US;
    mso-fareast-language:EN-GB'>NPC</span></b><span dir=RTL></span><b><span
    lang=AR-SA style='mso-bidi-font-size:14.0pt;font-family:"Calibri",sans-serif;
    mso-fareast-language:EN-GB'><span dir=RTL></span>)</span></b><b><span
    lang=EN-GB dir=LTR style='mso-bidi-font-size:14.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='text-indent:-.25in;line-height:
    115%;mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=EN-GB
    style='font-size:10.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:11.0pt;line-height:115%;
    font-family:"Times New Roman",serif'>الاتصال بالرقم الموحد:</span><span
    dir=LTR></span><span lang=AR-SA dir=LTR style='font-size:11.0pt;line-height:
    115%;font-family:"Times New Roman",serif'><span dir=LTR></span> </span><span
    dir=RTL></span><span lang=AR-SA style='font-size:11.0pt;line-height:115%;
    font-family:"Times New Roman",serif'><span dir=RTL></span>19999<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='text-indent:-.25in;line-height:
    115%;mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=EN-GB
    style='font-size:10.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:11.0pt;line-height:115%;
    font-family:"Times New Roman",serif'>البريد الإلكتروني: </span><span
    lang=EN-GB><a href="mailto:npc.drug@sfda.gov.sa"><span dir=LTR
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'>npc.drug@sfda.gov.sa</span></a></span><span
    lang=EN-GB dir=LTR style='font-size:11.0pt;line-height:115%;font-family:
    "Times New Roman",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='text-indent:-.25in;line-height:
    115%;mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=EN-GB
    style='font-size:10.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:11.0pt;line-height:115%;
    font-family:"Times New Roman",serif'>الموقع الإلكتروني: </span><span
    lang=EN-GB><a href="https://ade.sfda.gov.sa/"><span lang=EN-US dir=LTR
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-ansi-language:EN-US;mso-fareast-language:EN-GB'>https://ade.sfda.gov.sa</span></a></span><span
    lang=EN-GB dir=LTR style='mso-bidi-font-size:14.0pt;line-height:115%;
    font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span dir=RTL></span><b><span lang=AR-SA
    style='mso-bidi-font-size:14.0pt;font-family:"Traditional Arabic",serif'><span
    dir=RTL></span>- جلاكسو سميث كلاين – المكتب الرئيسي، جدة.</span></b><b><span
    lang=EN-GB dir=LTR style='mso-bidi-font-size:14.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='text-indent:-.25in;
    line-height:115%;mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-GB style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'>هاتف:
    6536666 (12) 966 +<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='text-indent:-.25in;
    line-height:115%;mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-GB style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'>جوال
    : 9882-904-56 </span><span dir=LTR></span><span lang=AR-SA dir=LTR
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'><span
    dir=LTR></span><span style='mso-spacerun:yes'> </span></span><span dir=RTL></span><span
    lang=AR-SA style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'><span
    dir=RTL></span>966 +<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='text-indent:-.25in;
    line-height:115%;mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-GB style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'>البريد
    اللكتروني : </span><span lang=EN-GB><a href="mailto:saudi.safety@gsk.com"><span
    dir=LTR style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-fareast-language:EN-US'>saudi.safety@gsk.com</span></a></span><span
    lang=AR-SA style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='text-indent:-.25in;
    line-height:115%;mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-GB style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'>الموقع
    الإلكتروني: </span><span lang=EN-GB><a href="https://gskpro.com/en-sa/"><span
    lang=EN-US dir=LTR style='font-size:11.0pt;line-height:115%;font-family:
    "Times New Roman",serif;mso-ansi-language:EN-US;mso-fareast-language:EN-GB'>https://gskpro.com/en-sa</span><span
    dir=RTL></span><span lang=AR-SA style='font-size:11.0pt;line-height:115%;
    font-family:"Times New Roman",serif;mso-fareast-language:EN-GB'><span
    dir=RTL></span>/</span></a></span><span lang=AR-SA style='font-size:11.0pt;
    line-height:115%;font-family:"Times New Roman",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='text-indent:-.25in;
    line-height:115%;mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-GB style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;line-height:115%;font-family:"Times New Roman",serif'>ص.ب
    55850، جدة 21544، المملكة العربية السعودية</span><span lang=AR-SA
    style='font-size:16.0pt;line-height:115%;font-family:"Traditional Arabic",serif'>.<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إن هذا دواء</strong></p><p dir="RTL">- الدواء مستحضر يؤثر على صحتك، وإستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">- اتبع بدقة وصفة الطبيب، وطريقة الإستعمال المنصوص عليها، وتعليمات الصيدلاني الذي صرفها لك.</p><p dir="RTL">- فالطبيب و الصيدلاني هما الخبيران بالدواء، وبنفعه و ضرره.</p><p dir="RTL">- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">- لا تكرر صرف الدواء بدون إستشارة الطبيب.</p><p dir="RTL">- احتفظ بجميع الأدوية بعيداً عن متناول الأطفال.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجلس وزراء الصحة العرب</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار :  UK issue 10 draft 1
	تاريخ الإصدار: 5 أغسطس 2021

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZOVIRAX I.V. 250 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZOVIRAX 250 mg: 250 mg aciclovir in each vial, the sodium ion content is approximately 26 mg per vial..

Excipients with known effect:
Sodium hydroxide

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Freeze dried powder for Intravenous Injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zovirax I.V. is indicated for the treatment of <em>Herpes simplex</em> infections in immunocompromised patients and severe initial genital herpes in the non-immunocompromised.</p><p>Zovirax I.V. is indicated for the prophylaxis of <em>Herpes simplex</em> infections in immunocompromised patients.</p><p>Zovirax I.V. is indicated for the treatment of <em>Varicella zoster</em> infections.</p><p>Zovirax I.V. is indicated for the treatment of herpes encephalitis.</p><p>Zovirax I.V. is indicated for the treatment of <em>Herpes simplex </em>infections in the neonate and infant up to 3 months of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Route of administration:</u><em> </em>Slow intravenous infusion over 1 hour.</p><p>A course of treatment with Zovirax I.V. usually lasts 5 days, but this may be adjusted according to the patient&#39;s condition and response to therapy. Treatment for herpes encephalitis usually lasts 10 days.&nbsp; Treatment for neonatal herpes infections usually lasts 14 days for mucocutaneous (skin-eye-mouth) infections and 21 days for disseminated or central nervous system disease.</p><p>The duration of prophylactic administration of Zovirax I.V. is determined by the duration of the period at risk.</p><p><u>Dosage in adults: </u></p><p>Patients with <em>Herpes simplex</em> (except herpes encephalitis) or <em>Varicella zoster </em>infections should be given Zovirax I.V. in doses of 5&nbsp;mg/kg body weight every 8 hours provided renal function is not impaired (see Dosage in renal impairment).</p><p>Immunocompromised patients with <em>Varicella zoster</em> infections or patients with herpes encephalitis should be given Zovirax I.V. in doses of 10 mg/kg body weight every 8 hours provided renal function is not impaired (see Dosage in renal impairment).</p><p>In obese patients dosed with intravenous aciclovir based on their actual body weight, higher plasma concentrations may be obtained (see 5.2 Pharmacokinetic properties).&nbsp; Consideration should therefore be given to dosage reduction in obese patients and especially in those with renal impairment or the elderly.</p><p><u>Dosage in infants and children:</u><em> </em>The dose of Zovirax I.V. for infants and children aged between 3 months and 12 years is calculated on the basis of body surface area.</p><p>Infants and children 3 months of age or older with<em> Herpes simplex</em> (except herpes encephalitis) or <em>Varicella zoster</em> infections should be given Zovirax I.V. in doses of 250&nbsp;mg per square metre of body surface area every 8 hours if renal function is not impaired.</p><p>In immunocompromised children with <em>Varicella zoster</em> infections or children with herpes encephalitis, Zovirax I.V. should be given in doses of 500&nbsp;mg per square metre body surface area every 8 hours if renal function is not impaired.</p><p>The dosage of Zovirax I.V. in neonates and infants up to 3 months of age is calculated on the basis of body weight.&nbsp;</p><p>The recommended regimen for infants treated for known or suspected neonatal herpes is aciclovir 20 mg/kg body weight IV every 8 hours for 21 days for disseminated and CNS disease, or for 14 days for disease limited to the skin and mucous membranes.</p><p>Infants and children with impaired renal function require an appropriately modified dose, according to the degree of impairment (see Dosage in renal impairment).</p><p>&nbsp;</p><p><u>Dosage in the elderly:</u></p><p>The possibility of renal impairment in the elderly must be considered and dosage should be adjusted accordingly (see <em>Dosage in renal impairment</em> below).</p><p>Adequate hydration should be maintained.</p><p><u>Dosage in renal impairment:</u></p><p>Caution is advised when administering Zovirax I.V. to patients with impaired renal function. Adequate hydration should be maintained.</p><p>Dosage adjustment for patients with renal impairment is based on creatinine clearance, in units of ml/min for adults and adolescents and in units of ml/min/1.73m<sup>2</sup> for infants and children less than 13 years of age.&nbsp; The following adjustments in dosage are suggested:</p><p>Dosage adjustments in adults and adolescents:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:536px"><tbody><tr><td style="vertical-align:top"><p><u>Creatinine Clearance</u></p></td><td style="vertical-align:top"><p><u>Dosage</u></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>25 to 50 ml/min</p></td><td style="vertical-align:top"><p>The dose recommended above (5 or 10 mg/kg body weight) should be given every 12 hours.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>10 to 25 ml/min</p></td><td style="vertical-align:top"><p>The dose recommended above (5 or 10 mg/kg body weight) should be given every 24 hours.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>0 (anuric) to 10 ml/min</p></td><td style="vertical-align:top"><p>In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose recommended above (5 or 10 mg/kg body weight) should be halved and administered every 24 hours.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>In patients receiving haemodialysis the dose recommended above (5 or 10 mg/kg body weight) should be halved and administered every 24 hours and after dialysis.</p></td></tr></tbody></table><p>Dosage adjustments in infants and children:</p><table border="0" cellspacing="0" cellpadding="0" style="width:536px"><tbody><tr><td style="vertical-align:top"><p><em><u>Creatinine Clearance</u></em></p></td><td style="vertical-align:top"><p><em><u>Dosage</u></em></p></td></tr><tr><td style="vertical-align:top"><p>25 to 50 ml/min/1.73m2</p></td><td style="vertical-align:top"><p>The dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 12 hours.</p><p><em><u>&nbsp;</u></em></p></td></tr><tr><td style="vertical-align:top"><p>10 to 25 ml/min/1.73m2</p></td><td style="vertical-align:top"><p>The dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 24 hours.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0 (anuric) to 10 ml/min/1.73m2</p></td><td style="vertical-align:top"><p>In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours.</p><p>In patients receiving haemodialysis the dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours and after dialysis</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to aciclovir or valaciclovir, or to any of the excipients listed in
section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adequate hydration should be maintained in patients given i.v. or high oral doses of aciclovir.</p><p>Intravenous doses should be given by infusion over one hour to avoid precipitation of aciclovir in the kidney; rapid or bolus injection should be avoided.</p><p>The risk of renal impairment is increased by use with other nephrotoxic drugs. Care is required if administering i.v. aciclovir with other nephrotoxic drugs.</p><p>&nbsp;</p><p><u>Use in patients with renal impairment and in elderly patients:</u></p><p>Aciclovir is eliminated by renal clearance, therefore the dose must be adjusted in patients with renal impairment (see section 4.2 Posology and method of administration).&nbsp; Elderly patients are likely to have reduced renal function and therefore the need for dose adjustment must be considered in this group of patients.&nbsp; Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects.&nbsp; In the reported cases, these reactions were generally reversible on discontinuation of treatment (see section 4.8 Undesirable effects).&nbsp; Prolonged or repeated courses of aciclovir in severely immune-compromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir treatment (see section 5.1).</p><p>In patients receiving Zovirax I.V. at higher doses (e.g. for herpes encephalitis) specific care regarding renal function should be taken, particularly when patients are dehydrated or have any renal impairment.</p><p>Reconstituted Zovirax I.V. has a pH of approximately 11 and should not be administered by mouth. Product contains sodium (26mg, approx. 1,13mmol). To be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p><p>Zovirax I.V. contains no antimicrobial preservative. Reconstitution and dilution should therefore be carried out under full aseptic conditions immediately before use and any unused solution discarded. The reconstituted or diluted solutions should not be refrigerated.</p><p><u>Other warnings and precautions</u></p><p>The labels shall contain the following statements:</p><p>For intravenous infusion only</p><p>Keep out of the reach and sight of children</p><p>Store below 25&deg;C</p><p>Prepare immediately prior to use</p><p>Discard unused solution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered concurrently that compete with this mechanism may increase aciclovir plasma concentrations. Probenecid and cimetidine increase the AUC of aciclovir by this mechanism and reduce aciclovir renal clearance. However no dosage adjustment is necessary because of the wide therapeutic index of aciclovir.</p><p>In patients receiving intravenous Zovirax caution is required during concurrent administration with drugs which compete with aciclovir for elimination, because of the potential for increased plasma concentrations of one or both drugs or their metabolites. Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are coadministered.</p><p>If <strong>lithium </strong>is administered concurrently with high dose aciclovir IV, the lithium serum concentration should be closely monitored because of the risk of lithium toxicity.</p><p>Care is also required (with monitoring for changes in renal function) if administering intravenous Zovirax with drugs which affect other aspects of renal physiology (e.g. cyclosporin, tacrolimus).</p><p>An experimental study on five male subjects indicates that concomitant therapy with aciclovir increases AUC of totally administered <strong>theophylline</strong> with approximately 50%. It is recommended to measure plasma concentrations during concomitant therapy with aciclovir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility:</u></p><p>There is no information on the effect of aciclovir on human female fertility.&nbsp;</p><p>In a study of 20 male patients with normal sperm count, oral aciclovir administered at doses of up to 1g per day for up to six months has been shown to have no clinically significant effect on sperm count, motility or morphology.</p><p>See clinical studies in section 5.2</p><p>&nbsp;</p><p><u>Pregnancy:</u></p><p>A post-marketing aciclovir pregnancy registry has documented pregnancy outcomes in women exposed to any formulation of Zovirax. The registry findings have not shown an increase in the number of birth defects amongst aciclovir exposed subjects compared to with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause. Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice. In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced.&nbsp; The clinical relevance of these findings is uncertain.</p><p>Caution should therefore be exercised by balancing the potential benefits of treatment against any possible hazard. Findings from reproduction toxicology studies are included in Section 5.3.</p><p><u>Breast-feeding:</u></p><p>Following oral administration of 200 mg five times a day, aciclovir has been detected in human breast milk at concentrations ranging from 0.6 to 4.1 times the corresponding plasma concentrations. These concentrations would potentially expose nursing infants to aciclovir dosages of up to 0.3 mg/kg body weight/day. Caution is therefore advised if Zovirax is to be administered to a nursing woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aciclovir i.v. for infusion is generally used in an in-patient hospital population and information on ability to drive and operate machinery is not usually relevant. There have been no studies to investigate the effect of aciclovir on driving performance or the ability to operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.</p><p>The following convention has been used for the classification of undesirable effects in terms of frequency:- Very common &sup3; 1/10, common &sup3; 1/100 and &lt; 1/10, uncommon &sup3; 1/1,000 and &lt; 1/100, rare &sup3; 1/10,000 and &lt; 1/1,000, very rare &lt; 1/10,000.</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders:</u></p><p>Uncommon: decreases in haematological indices (anaemia, thrombocytopenia, leukopenia).</p><p><u>Immune system disorders:</u></p><p>Very rare: anaphylaxis.</p><p><u>Psychiatric and nervous system disorders:</u></p><p>Very rare: headache, dizziness, agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, somnolence, encephalopathy, coma.</p><p>The above events are generally reversible and usually reported in patients with renal impairment or with other predisposing factors (see 4.4 Special Warnings and Precautions for Use).</p><p><u>Vascular disorders: </u></p><p>Common: phlebitis.</p><p><u>Respiratory, thoracic and mediastinal disorders:</u></p><p>Very rare: dyspnoea.</p><p><u>Gastrointestinal disorders:</u></p><p>Common: nausea, vomiting.</p><p>Very rare: diarrhoea, abdominal pain.</p><p><u>Hepato-biliary disorders:</u></p><p>Common: reversible increases in liver-related enzymes.</p><p>Very rare: reversible increases in bilirubin, jaundice, hepatitis.</p><p><u>Skin and subcutaneous tissue disorders:</u></p><p>Common: pruritus, urticaria, rashes (including photosensitivity).</p><p>Very rare: angioedema.</p><p><u>Renal and urinary disorders:</u></p><p>Common: increases in blood urea and creatinine.</p><p>Rapid increases in blood urea and creatinine concentrations are believed to be related to the peak plasma concentrations and the state of hydration of the patient. To avoid this effect the drug should not be given as an intravenous bolus injection but by slow infusion over a one-hour period.</p><p>Very rare: renal impairment, acute renal failure and renal pain.</p><p>Adequate hydration should be maintained. Renal impairment usually responds rapidly to rehydration of the patient and/or dosage reduction or withdrawal of the drug. Progression to acute renal failure however, can occur in exceptional cases.</p><p>Renal pain may be associated with renal failure and crystalluria.</p><p><u>General disorders and administration site conditions:</u></p><p>Very rare: fatigue, fever, local inflammatory reactions</p><p>Severe local inflammatory reactions sometimes leading to breakdown of the skin have occurred when Zovirax I.V. has been inadvertently infused into extracellular tissues.</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/ &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact</strong><strong>:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosage of intravenous aciclovir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with overdosage.&nbsp;</p><p>Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the blood and may, therefore, be considered an option in the management of overdose of this drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Direct acting antivirals, Nucleosides and nucleotides excl. reverse transcriptase inhibitors</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ATC code: J05AB01.</p><p>&nbsp;</p><p>Aciclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against human herpes viruses, including Herpes simplex virus types 1 and 2 and Varicella zoster virus (VZV), Epstein Barr virus (EBV) and Cytomegalovirus (CMV).&nbsp; In cell culture aciclovir has the greatest antiviral activity against HSV-1, followed (in decreasing order of potency) by HSV-2, VZV, EBV and CMV.</p><p>The inhibitory activity of aciclovir for HSV-1, HSV-2, VZV and EBV is highly selective.&nbsp; The enzyme thymidine kinase (TK) of normal, uninfected cells does not use aciclovir effectively as a substrate, hence toxicity to mammalian host cells is low; however, TK encoded by HSV, VZV and EBV converts aciclovir to aciclovir monophosphate, a nucleoside analogue, which is further converted to the diphosphate and finally to the triphosphate by cellular enzymes. Aciclovir triphosphate interferes with the viral DNA polymerase and inhibits viral DNA replication with resultant chain termination following its incorporation into the viral DNA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Aciclovir is only partially absorbed from the gut. The average oral bioavailability varies between 10 and 20%. Under fasting conditions, mean peak concentrations (C<sub>max</sub>) of 0.4 microgram/ml are achieved at approximately 1.6 hours after a 200 mg dose administered as oral suspension or capsule. Mean peak plasma concentrations (C<sub>ssmax</sub>) increase to 0.7 microgram/ml (3.1 micromoles) at steady state following doses of 200 mg administered every four hours. A less than proportional increase is observed for C<sub>ssmax</sub> concentrations following doses of 400 mg and 800 mg administered four-hourly, with values reaching 1.2 and 1.8 microgram/ml (5.3 and 8 micromoles), respectively.</p><p><strong>Distribution</strong></p><p>The mean volume of distribution of 26 L indicates that aciclovir is distributed within total body water. Apparent values after oral administration (Vd/F) ranged from 2.3 to 17.8 L/kg. As plasma protein binding is relatively low (9 to 33%), drug interactions involving binding site displacement are not anticipated. Cerebrospinal fluid concentrations are approximately 50% of corresponding plasma concentrations at steady-state.</p><p><strong>Metabolism</strong></p><p>Aciclovir is predominantly excreted unchanged by the kidney. The only significant urinary metabolite is 9-[(carboxymethoxy) methyl]guanine, and accounts for 10-15% of the dose excreted in the urine.</p><p><strong>Elimination</strong></p><p>In adults, mean systemic exposure (AUC0-&infin;) to aciclovir ranges between 1.9 and 2.2 microgram*h/mL after a 200 mg dose. At this dose, the mean terminal plasma half-life after oral administration has been shown to vary between 2.8 and 4.1 hours.</p><p>&nbsp;</p><p>In adults, the terminal plasma half-life of aciclovir after administration of Zovirax I.V. is about 2.9 hours. Renal clearance of aciclovir (CLr= 14.3 L/h) is substantially greater than creatinine clearance, indicating that tubular secretion, in addition to glomerular filtration, contributes to the renal elimination of the drug The half-life and total clearance of aciclovir are dependent on renal function. Therefore, dosage adjustment is recommended for renally impaired patients.</p><p>&nbsp;</p><p>In adults, mean steady state peak plasma concentrations (Cssmax) following a one-hour infusion of 2.5&nbsp;mg/kg, 5&nbsp;mg/kg and 10&nbsp;mg/kg were 22.7&nbsp;micromolar (5.1&nbsp;microgram/ml), 43.6&nbsp;micromolar (9.8&nbsp;microgram/ml) and 92&nbsp;micromolar (20.7&nbsp;microgram/ml) respectively.&nbsp; The corresponding trough concentrations(Cssmin) 7 hours later were 2.2&nbsp;micromolar (0.5&nbsp;microgram/ml), 3.1&nbsp;micromolar (0.7&nbsp;microgram/ml) and 10.2&nbsp;micromolar (2.3&nbsp;microgram/ml) respectively.&nbsp; In children over 1 year of age similar mean peak (Cssmax) and trough (Cssmin) concentrations were observed when a dose of 250&nbsp;mg/m<sup>2</sup>&nbsp;was substituted for 5&nbsp;mg/kg and a dose of 500&nbsp;mg/m2 was substituted for 10&nbsp;mg/kg.</p><p>&nbsp;</p><p>In neonates (0 to 3 months of age) treated with doses of 10&nbsp;mg/kg administered by infusion over a one-hour period every 8 hours the Cssmax was found to be 61.2&nbsp;micromolar (13.8&nbsp;microgram/ml) and the Cssmin to be 10.1 micromolar (2.3&nbsp;microgram/ml).&nbsp; A separate group of neonates treated with 15&nbsp;mg/kg every 8 hours showed approximate dose proportional increases, with a Cmax of 83.5&nbsp;micromolar (18.8&nbsp;microgram/ml) and Cmin of 14.1&nbsp;micromolar (3.2&nbsp;microgram/ml). The terminal plasma half-life in these patients was 3.8 hours.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Special Patient Populations</u></strong></p><p><u>Elderly</u></p><p>In the elderly patients with normal renal function total clearance falls with increasing age due to decreases in creatinine clearance . However, the possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>In patients with chronic renal failure the mean terminal half-life was found to be 19.5 hours. The mean aciclovir half-life during haemodialysis was 5.7 hours. Plasma aciclovir concentrations dropped approximately 60% during dialysis.</p><p><u>Weight</u></p><p>In a clinical study in which morbidly obese female patients (n=7) were dosed with intravenous aciclovir based on their actual body weight, plasma concentrations were found to be approximately twice that of normal weight patients (n=5), consistent with the difference in body weight between the two groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mutagenicity:</u></p><p>The results of a wide range of mutagenicity tests<em> in vitro </em>and<em> in vivo</em> indicate that aciclovir is unlikely to pose a genetic risk to man.</p><p><u>Carcinogenicity:</u></p><p>Aciclovir was not found to be carcinogenic in long-term studies in the rat and the mouse.</p><p><u>Teratogenicity:</u></p><p>Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice</p><p>In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced.&nbsp; The clinical relevance of these findings is uncertain.</p><p><u>Fertility:</u></p><p>Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of aciclovir greatly in excess of those employed therapeutically. Two-generation studies in mice did not reveal any effect of (orally administered) aciclovir on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydroxide (used to adjust pH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25oC</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass vials closed with butyl or bromobutyl rubber stoppers secured by aluminium collars.</p><p>17 ml-nominal capacity of vial containing 250 mg aciclovir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Reconstitution: </em>Zovirax I.V. should be reconstituted using the following volumes of either Water for Injections BP or Sodium Chloride Intravenous Injection BP (0.9% w/v) to provide a solution containing 25&nbsp;mg aciclovir per ml:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Formulation</em></p></td><td style="vertical-align:top"><p><em>Volume of fluid for reconstitution</em></p></td></tr><tr><td style="vertical-align:top"><p>250 mg vial</p></td><td style="vertical-align:top"><p>10 ml</p></td></tr></tbody></table><p>&nbsp;</p><p>From the calculated dose, determine the appropriate number and strength of vials to be used.&nbsp; To reconstitute each vial add the recommended volume of infusion fluid and shake gently until the contents of the vial have dissolved completely.</p><p><u>Administration:</u><em> </em></p><p>The required dose of Zovirax I.V. should be administered by slow intravenous infusion over a one-hour period.</p><p>After reconstitution Zovirax I.V. may be administered by a controlled-rate infusion pump.</p><p>Alternatively, the reconstituted solution may be further diluted to give an aciclovir concentration of not greater than 5&nbsp;mg/ml (0.5% w/v) for administration by infusion:</p><p>Add the required volume of reconstituted solution to the chosen infusion solution, as recommended below, and shake well to ensure adequate mixing occurs.</p><p>For children and neonates, where it is advisable to keep the volume of infusion fluid to a minimum, it is recommended that dilution is on the basis of 4&nbsp;ml reconstituted solution (100&nbsp;mg aciclovir) added to 20&nbsp;ml of infusion fluid.</p><p>For adults, it is recommended that infusion bags containing 100&nbsp;ml of infusion fluid are used, even when this would give an aciclovir concentration substantially below 0.5% w/v.&nbsp; Thus one 100&nbsp;ml infusion bag may be used for any dose between 250&nbsp;mg and 500&nbsp;mg aciclovir (10 and 20&nbsp;ml of reconstituted solution) but a second bag must be used for doses between 500 mg and 1000&nbsp;mg.</p><p>When diluted in accordance with the recommended schedules, Zovirax I.V. is known to be compatible with the following infusion fluids and stable for up to 12 hours at room temperature (15<!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span>SYMBOL 176 \f
&quot;Symbol&quot;</span><![endif]--><!--[if supportFields]><span lang=EN-GB><span
style='mso-element:field-end'></span></span><![endif]-->C to 25<!--[if supportFields]><span lang=EN-GB><span style='mso-element:field-begin'></span>SYMBOL
176 \f &quot;Symbol&quot;</span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]-->C):</p><p>Sodium Chloride Intravenous Infusion BP (0.45% and 0.9% w/v)</p><p>Sodium Chloride (0.18% w/v) and Glucose (4% w/v) Intravenous Infusion BP</p><p>Sodium Chloride (0.45% w/v) and Glucose (2.5% w/v) Intravenous Infusion BP</p><p>Compound Sodium Lactate Intravenous Infusion BP (Hartmann&#39;s Solution).</p><p>Zovirax I.V. when diluted in accordance with the above schedule will give an aciclovir concentration not greater than 0.5% w/v.</p><p>Since no antimicrobial preservative is included, reconstitution and dilution must be carried out under full aseptic conditions, immediately before use, and any unused solution discarded.</p><p>Should any visible turbidity or crystallisation appear in the solution before or during infusion, the preparation should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
GlaxoSmithKline S.p.A *, Parma – Italy
Marketing Authorization holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
  *member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version Number: UK SPC Issue 13 draft 1
Date of Issue: 05 August 2021

ZOVIRAX is a trademark owned by or licensed to GSK group of companies
© 2023 GSK group of companies, all rights reserved.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>